Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb 7, 2019	Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference PRINCETON, N.J. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the 2019 BIO CEO & Investor conference on Tuesday February 12, 2019 at 10:30 AM...	Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference 13.9 KB
Toggle SummaryJan 10, 2019	Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance Discussions with FDA on Design of Comparative Wear Study of Twirla ® and Xulane ® Completed Cash Expected to Enable Company to Fund Operations into Second Quarter of 2019 PRINCETON, N.J. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company,...	Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance 38 KB
Toggle SummaryDec 18, 2018	Agile Therapeutics to Present at Biotech Showcase 2019 PRINCETON, N.J. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2019 on Tuesday January 8, 2019 at 10:00 AM Pacific...	Agile Therapeutics to Present at Biotech Showcase 2019 24.9 KB
Toggle SummaryDec 13, 2018	Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® Expects to Announce Results of Meeting After Receipt of Final Minutes from FDA PRINCETON, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced that on December 11, 2018 , it met with the U.S....	Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® 34.7 KB
Toggle SummaryNov 1, 2018	Agile Therapeutics Reports Third Quarter 2018 Financial Results Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and nine months ended September 30, 2018 and...	Agile Therapeutics Reports Third Quarter 2018 Financial Results 95.1 KB
Toggle SummaryOct 24, 2018	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) PRINCETON, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced an oral presentation regarding predictors of pregnancy in the Phase 3 SECURE study of the investigational low-dose, once-weekly contraceptive patch,...	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) 34.3 KB
Toggle SummaryOct 9, 2018	Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA PRINCETON, N.J. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has received a response from FDA’s Office of New Drugs (“OND”) concerning the Company’s formal dispute resolution request. The Company had appealed...	Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA 36.3 KB
Toggle SummaryAug 3, 2018	Agile Therapeutics Reports Second Quarter 2018 Financial Results Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and six months ended June 30, 2018 and provided a...	Agile Therapeutics Reports Second Quarter 2018 Financial Results 81 KB
Toggle SummaryJul 24, 2018	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request Company Plans to Appeal to the FDA’s Office of New Drugs PRINCETON, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX) (the “Company”), a women’s healthcare company, today announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has...	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request 23.4 KB
Toggle SummaryJun 7, 2018	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , June 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX), a women’s healthcare company, today announced several key corporate updates: Formal dispute resolution request has been...	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance 26.1 KB